CAVO M.

In this paper, an optimization algorithm based on a Mixed-Integer Linear Programming (MILP) solver is developed to determine the best energy generation solutions for marine applications. Environmentally sustainable systems (e.g., fuel cells and batteries), heat recovery devices (e.g., HRSG and Organic Rankine Cycles) and traditional power...

No description

As the interest in hydrogen and PEM fuel cells is growing, it is crucial to define the best technology for fuel storage, especially in the transportation field. Metal hydrides show different benefits, including the possibility of thermally coupling the hydrogen storage and utilization systems: fuel cells require heat subtraction for ensuring...

Pressurized Polymeric Electrolyte Membrane Fuel Cell (PEMFC) systems are growing among electrical power generation systems, as a zero-emissions technology. In this framework, the University of Genoa have been modelling an innovative concept for the application of low-temperature fuel cells. A turbocharged proton exchange membrane fuel cell...

The design and management of a ship power system determine the amount of CO2 emitted during the ship operations. Recently, the International Maritime Organization has introduced the Carbon Intensity Indicator to limit the environmental impact of ships, pushing designers to define new solutions to reduce polluting emissions. The proposed...

No description

Carfilzomib–lenalidomide–dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis of 197 RRMM patients (pts) between January 2016 and March 2018 in six Italian hematologic centers, with the aim to evaluate efficacy and safety of KRd in real-life. At KRd...

Subcutaneous (SC) bortezomib-based regimens represent the standard induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients. Published data are based principally on intravenous (IV) administration: this retrospective observational study aimed to define patients' outcomes upon SC...

Plerixafor inhibits CXCR4, thus inducing the mobilization of hematopoietic stem/progenitor cells in lymphoma and multiple myeloma (MM) patients eligible for autologous stem cell transplantation (ASCT). However, the kinetics of plerixafor-induced mobilization of lymphocyte subsets is poorly known. Here, we evaluated the graft content, the...